SYNTIMMUNE
Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. Laurence and Richard Blumberg founded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts.
SYNTIMMUNE
Social Links:
Industry:
Biotechnology Emergency Medicine Health Care Medical Pharmaceutical
Founded:
2013-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.syntimmune.com
Total Employee:
11+
Status:
Active
Contact:
617-206-4220
Email Addresses:
[email protected]
Total Funding:
76 M USD
Technology used in webpage:
SPF Amazon ReCAPTCHA Amazon Route 53 Amazon CloudFront
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montréal and Lévis.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
ZS Pharma
ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Apple Tree Partners
Apple Tree Partners investment in Series B - Syntimmune
Partners Innovation Fund
Partners Innovation Fund investment in Series B - Syntimmune
Baxalta Ventures
Baxalta Ventures investment in Series B - Syntimmune
Partners Innovation Fund
Partners Innovation Fund investment in Series A - Syntimmune
Baxalta Ventures
Baxalta Ventures investment in Series A - Syntimmune
Apple Tree Partners
Apple Tree Partners investment in Series A - Syntimmune
Baxalta Ventures
Baxalta Ventures investment in Series A - Syntimmune
Partners Innovation Fund
Partners Innovation Fund investment in Series A - Syntimmune
Apple Tree Partners
Apple Tree Partners investment in Series A - Syntimmune
Baxalta Ventures
Baxalta Ventures investment in Series A - Syntimmune
Official Site Inspections
http://www.syntimmune.com
- Host name: server-3-168-102-30.jfk52.r.cloudfront.net
- IP address: 3.168.102.30
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
